PT  - JOURNAL ARTICLE
AU  - Kiti, Moses C.
AU  - Aguolu, Obianuju G.
AU  - Zelaya, Alana
AU  - Chen, Holin Y.
AU  - Ahmed, Noureen
AU  - Battross, Jonathan
AU  - Liu, Carol Y.
AU  - Nelson, Kristin N.
AU  - Jenness, Samuel M.
AU  - Melegaro, Alessia
AU  - Ahmed, Faruque
AU  - Malik, Fauzia
AU  - Omer, Saad B.
AU  - Lopman, Ben A.
TI  - Changing social contact patterns among US workers during the COVID-19 pandemic: April 2020 to December 2021
AID  - 10.1101/2022.12.19.22283700
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.12.19.22283700
4099  - http://medrxiv.org/content/early/2022/12/20/2022.12.19.22283700.short
4100  - http://medrxiv.org/content/early/2022/12/20/2022.12.19.22283700.full
AB  - Non-pharmaceutical interventions minimize social contacts, hence the spread of SARS-CoV-2. We quantified two-day contact patterns among USA employees from 2020–2021 during the COVID-19 pandemic. Contacts were defined as face-to-face conversations, involving physical touch or proximity to another individual and were collected using electronic diaries. Mean (standard deviation) contacts reported by 1,456 participants were 2.5 (2.5), 8.2 (7.1), 9.2 (7.1) and 10.1 (9.5) across round 1 (April–June 2020), 2 (November 2020–January 2021), 3 (June–August 2021), and 4 (November–December 2021), respectively. Between round 1 and 2, we report a 3-fold increase in the mean number of contacts reported per participant with no major increases from round 2–4. We modeled SARS-CoV-2 transmission at home, work, and community. The model revealed reduced relative transmission in all settings in round 1. Subsequently, transmission increased at home and in the community but remained very low in work settings. Contact data are important to parameterize models of infection transmission and control.Teaser Changes in social contact patterns shape disease dynamics at workplaces in the USA.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by CDC/NCEZID grant 5U01CK00057, NIH/NICHD grant 5R01HD097175, and the European Research Council Consolidator Grant IMMUNE Project grant 101003183. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB of Yale University gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.